- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Cyanomethyl.
Displaying page 1 of 1.
EudraCT Number: 2004-002952-33 | Sponsor Protocol Number: CAAE581A2203E1 | Start Date*: 2005-03-17 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for... | ||
Medical condition: Osteoporosis is a metabolic bone disease characterized by low bone mass and micro architectural deterioration of bone tissue, leading to enhanced fragility and a consequent increase in fracture risk. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SK (Prematurely Ended) AT (Completed) IT (Prematurely Ended) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002243-25 | Sponsor Protocol Number: CAAE581A2203E2 | Start Date*: 2007-08-28 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis | ||
Medical condition: Osteoporosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: PL (Completed) FR (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001754-92 | Sponsor Protocol Number: AAE581C2201 | Start Date*: 2005-02-14 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg t... | ||
Medical condition: Osteoarthritis (OA) is a disease with a complex pathophysiology leading to the degeneration of articular cartilage and bone. It is characterized by pain, biochemical and enzymatic changes, cartilag... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-022280-35 | Sponsor Protocol Number: SSD113434 | Start Date*: 2010-11-22 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis. | |||||||||||||
Medical condition: subjects with moderate or severe atopic dermatitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
